Cisplatin
- Generic Name
- Cisplatin
- Brand Names
- Platinol
- Drug Type
- Small Molecule
- Chemical Formula
- Cl2H6N2Pt
- CAS Number
- 15663-27-1
- Unique Ingredient Identifier
- Q20Q21Q62J
- Background
Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.
- Indication
For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.
- Associated Conditions
- Advanced Ovarian Cancer, Ovarian Cancer Metastatic, Advanced Bladder cancer, Advanced Testicular cancer, Metastatic Testicular cancer
- Associated Therapies
- -
SBRT Combined With PD-1 Antibody and Chemotherapy in Oligometastatic Nasopharyngeal Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2022-09-01
- Last Posted Date
- 2024-06-28
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 41
- Registration Number
- NCT05524168
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
AK104 Alone or in Combination With Chemotherapy in the First-line Treatment of ESCC
- Conditions
- Interventions
- First Posted Date
- 2022-08-31
- Last Posted Date
- 2022-08-31
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 80
- Registration Number
- NCT05522894
Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-08-30
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 42
- Registration Number
- NCT05521997
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
Neoadjuvant Chemotherapy, Tislelizumab With Afatinib for HNSCC
- Conditions
- Interventions
- First Posted Date
- 2022-08-25
- Last Posted Date
- 2023-12-29
- Lead Sponsor
- West China Hospital
- Target Recruit Count
- 28
- Registration Number
- NCT05516589
- Locations
- 🇨🇳
West China Hospital, Sichuan University, Chengdu, Sichuan, China
Preoperative Nab-paclitaxel, Cisplatin, and Gemcitabine Chemotherapy With or Without Infigratinib Targeted Therapy for the Treatment of Resectable Intrahepatic Cholangiocarcinoma, The OPTIC Trial
- Conditions
- Interventions
- First Posted Date
- 2022-08-25
- Last Posted Date
- 2023-12-26
- Lead Sponsor
- Emory University
- Registration Number
- NCT05514912
Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-08-16
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 792
- Registration Number
- NCT05502237
- Locations
- 🇦🇷
Clínica Viedma, Viedma, Argentina
🇦🇹Klinikum Klagenfurt am Woerthersee, Klagenfurt Am Woerthersee, Austria
🇺🇸Eastern CT Hematology and Oncology Associates, Norwich, Connecticut, United States
Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2022-08-11
- Last Posted Date
- 2024-03-05
- Lead Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Target Recruit Count
- 44
- Registration Number
- NCT05498220
- Locations
- 🇺🇸
Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States
Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer
- First Posted Date
- 2022-08-09
- Last Posted Date
- 2024-05-02
- Lead Sponsor
- EQRx International, Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT05493501
- Locations
- 🇺🇸
Northwest Medical Specialties, PLLC, Tacoma, Washington, United States
🇺🇸QCCA - Mission Blood & Cancer, Des Moines, Iowa, United States
🇺🇸Memorial Cancer Institute, Pembroke Pines, Florida, United States
The Management of Metastatic Neck Nodes in N2/3 Hypopharyngeal Squamous Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2022-08-09
- Last Posted Date
- 2023-04-18
- Lead Sponsor
- Eye & ENT Hospital of Fudan University
- Target Recruit Count
- 111
- Registration Number
- NCT05494190
- Locations
- 🇨🇳
Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
🇨🇳Shandong Provincial ENT Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China
🇨🇳Eye & ENT Hospital, Fudan University, Shanghai, Shanghai, China
A Study of Reduced Radiation Therapy and Standard-of-Care Chemotherapy in People With HPV-Positive Throat Cancer
- First Posted Date
- 2022-08-08
- Last Posted Date
- 2024-05-09
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 121
- Registration Number
- NCT05491512
- Locations
- 🇺🇸
Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States
🇺🇸Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering Cancer Center at Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.